83 related articles for article (PubMed ID: 11287818)
1. Encapsulation in cationic liposomes enhances antitumour efficacy and reduces the toxicity of etoposide, a topo-isomerase II inhibitor.
Sengupta S; Tyagi P; Chandra S; Kochupillai V; Gupta SK
Pharmacology; 2001; 62(3):163-71. PubMed ID: 11287818
[TBL] [Abstract][Full Text] [Related]
2. Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies.
Sengupta S; Tyagi P; Velpandian T; Gupta YK; Gupta SK
Pharmacol Res; 2000 Nov; 42(5):459-64. PubMed ID: 11023708
[TBL] [Abstract][Full Text] [Related]
3. Tuftsin augments antitumor efficacy of liposomized etoposide against fibrosarcoma in Swiss albino mice.
Khan A; Khan AA; Dwivedi V; Ahmad MG; Hakeem S; Owais M
Mol Med; 2007; 13(5-6):266-76. PubMed ID: 17622310
[TBL] [Abstract][Full Text] [Related]
4. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
5. Etoposide incorporated into camel milk phospholipids liposomes shows increased activity against fibrosarcoma in a mouse model.
Maswadeh HM; Aljarbou AN; Alorainy MS; Alsharidah MS; Khan MA
Biomed Res Int; 2015; 2015():743051. PubMed ID: 25821817
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
Rose PG; Rodriguez M; Walker J; Greer B; Fusco N; McGuire W
Gynecol Oncol; 2002 Apr; 85(1):136-9. PubMed ID: 11925133
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study.
Evans SR; Krown SE; Testa MA; Cooley TP; Von Roenn JH
J Clin Oncol; 2002 Aug; 20(15):3236-41. PubMed ID: 12149296
[TBL] [Abstract][Full Text] [Related]
8. Potential usage of liposomal 4beta-aminoalkyl-4'-O-demethyl-4-desoxypodophyllotoxin (TOP-53) for cancer chemotherapy.
Shimizu K; Takada M; Asai T; Irimura K; Baba K; Oku N
Biol Pharm Bull; 2002 Jun; 25(6):783-6. PubMed ID: 12081147
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of the tumour inhibitory activity, in vivo, of diospyrin, a plant-derived quinonoid, through liposomal encapsulation.
Hazra B; Kumar B; Biswas S; Pandey BN; Mishra KP
Toxicol Lett; 2005 Jun; 157(2):109-17. PubMed ID: 15836998
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tissue distribution of liposomal etoposide in rats.
Sistla A; Smith DJ; Kobrinsky NL; Kumar K
Drug Deliv; 2009 Nov; 16(8):423-9. PubMed ID: 19839786
[TBL] [Abstract][Full Text] [Related]
11. TPGS-modified liposomes for the delivery of ginsenoside compound K against non-small cell lung cancer: formulation design and its evaluation in vitro and in vivo.
Yang L; Xin J; Zhang Z; Yan H; Wang J; Sun E; Hou J; Jia X; Lv H
J Pharm Pharmacol; 2016 Sep; 68(9):1109-18. PubMed ID: 27368109
[TBL] [Abstract][Full Text] [Related]
12. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
13. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
[TBL] [Abstract][Full Text] [Related]
14. Formulation of plumbagin loaded long circulating pegylated liposomes: in vivo evaluation in C57BL/6J mice bearing B16F1 melanoma.
Kumar MR; Aithal BK; Udupa N; Reddy MS; Raakesh V; Murthy RS; Raju DP; Rao BS
Drug Deliv; 2011; 18(7):511-22. PubMed ID: 21793763
[TBL] [Abstract][Full Text] [Related]
15. Liposomal vincristine for the treatment of human acute lymphoblastic leukaemia in severe combined immunodeficient (SCID) mice.
Millar JL; Millar BC; Powles RL; Steele JP; Clutterbuck RD; Mitchell PL; Cox G; Forssen E; Catovsky D
Br J Haematol; 1998 Aug; 102(3):718-21. PubMed ID: 9722298
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer.
Planting A; Kho S; van der Burg M; Goey H; Schellens J; van den Bent M; van der Gaast A; de Boer-Dennert M; Stoter G; Verweij J
Cancer Chemother Pharmacol; 1997; 40(4):347-52. PubMed ID: 9225954
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel encapsulated in cationic liposomes: a new option for neovascular targeting for the treatment of prostate cancer.
Bode C; Trojan L; Weiss C; Kraenzlin B; Michaelis U; Teifel M; Alken P; Michel MS
Oncol Rep; 2009 Aug; 22(2):321-6. PubMed ID: 19578772
[TBL] [Abstract][Full Text] [Related]
18. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors.
Mayer LD; Dougherty G; Harasym TO; Bally MB
J Pharmacol Exp Ther; 1997 Mar; 280(3):1406-14. PubMed ID: 9067330
[TBL] [Abstract][Full Text] [Related]
19. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
20. A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention.
Ramsay E; Alnajim J; Anantha M; Zastre J; Yan H; Webb M; Waterhouse D; Bally M
Eur J Pharm Biopharm; 2008 Mar; 68(3):607-17. PubMed ID: 17904831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
